The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 trial of retifanlimab (anti–PD-1) in combination with INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti–TIM-3) as first-line treatment in patients with PD-L1–positive recurrent/metastatic squamous cell carcinoma of the head and neck.
 
Ezra E.W. Cohen
Leadership - Ayala Pharmaceuticals; Kura Oncology; Psioxus Therapeutics
Stock and Other Ownership Interests - Kinnate Biopharma; Primmune Therapeutics
Consulting or Advisory Role - Axelia; Cel-Sci; Eisai; Hookipa Biotech; ImmunoSensor; Istari; Janssen; Kahr Medical; Mana Therapeutics; Merck; Mirati Therapeutics; MSD; Nectin Tx; Pangea; Roche
 
Christophe Le Tourneau
Honoraria - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Novartis; Rakuten Medical; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD
 
Richard Schaub
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Matthias Bartenstein
Employment - Boehringer Ingelheim (I); Incyte
Stock and Other Ownership Interests - Incyte
 
Lulu Cheng
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Lisa F. Licitra
Consulting or Advisory Role - ACC Med+Logistics; Adlai Nortye; AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Debiopharm Group; Eisai; Exelixis; GlaxoSmithKline; IRX Therapeutics; Medpace; Merck Serono; MSD; Neutron Therapeutics; Novartis; Pfizer; Roche; Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Debiopharm Group (Inst); Eisai (Inst); Exelixis (Inst); IRX Therapeutics (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)